Overview
- The Lefkowitz laboratory published the results on Wednesday, June 24, 2026, reporting three drug-like molecules that directly bind β‑arrestins and block their function.
- One compound called Cmpd-5 was visualized by cryo-electron microscopy binding a previously unknown pocket on β‑arrestin and causing a shape change that prevents receptor engagement.
- In cell tests the molecules stopped β‑arrestin recruitment, receptor desensitization, internalization, and arrestin-specific signaling while leaving G protein signaling intact.
- The compounds were found by an unbiased screen of the National Cancer Institute compound library and were validated in engineered human cells and in physiologically relevant immune and heart muscle cells.
- Researchers say these molecules are first-in-class chemical probes that will help study transducer-specific GPCR biology and could guide pathway-targeted therapies, but they remain at an early preclinical stage needing in vivo testing and optimization.